By Gina Shaw
Las Vegas—What’s more important—pharmacokinetics or price—when it comes to adoption of biosimilars in the United States?
According to Sanford & Bernstein senior analyst Ronny Gal,
PhD, economic incentives for biosimilar adoption aimed at providers and payors
will have the largest influence, rather than any clinical differences between a
biosimilar and its reference product.
“When doctors have a [financial] incentive to adopt biosimilars,